Upacicalcet → (2S)-2-amino-3-{[(3-sulfophenyl)carbamoyl]amino}propanoic acid
반응식
[NH2:1][C@@H:2]([CH2:6][NH:7][C:8](=[O:22])[NH:9][C:10]1[CH:15]=[C:14](Cl)[CH:13]=[C:12]([S:17]([OH:20])(=[O:19])=[O:18])[C:11]=1O)[C:3]([OH:5])=[O:4].N[C@@H](CNC(=O)NC1C=C(S(O)(=O)=O)C(C)=C(Cl)C=1)C(O)=O.N[C@@H](CNC(=O)NC1C=C(S(O)(=O)=O)C=C(Cl)C=1C)C(O)=O>>[NH2:1][C@@H:2]([CH2:6][NH:7][C:8](=[O:22])[NH:9][C:10]1[CH:15]=[CH:14][CH:13]=[C:12]([S:17]([OH:20])(=[O:19])=[O:18])[CH:11]=1)[C:3]([OH:5])=[O:4]참가 물질
4
실험 절차
Above all, (2S)-2-amino-3-{[(5-chloro-2-hydroxy-3-sulfophenyl)carbamoyl]amino}propanoic acid, (2S)-2-amino-3-{[(3-chloro-4-methyl-5-sulfophenyl)carbamoyl]amino}propanoic acid and (2S)-2-amino-3-{[(3-chloro-2-methyl-5-sulfophenyl)carbamoyl]amino}propanoic acid, or salts thereof, are particularly preferable as a compound that is used as a prophylactic or therapeutic agent for diabetes or obesity of the present invention.